Hemp Oil Dosage Information - Written by Rick Simpson

Interesting PBS video on Cannabinoids

Cannabinoid 'Completely' Prevents Chemotherapy-Induced Neuropathy, Study Says

link

Wednesday, 19 October 2011

Philadelphia, PA: The administration of the non-psychotropic plant cannabinoid cannabidiol (CBD) 'completely prevents' the onset of nerve pain associated with chemotherapy treatment, according to preclinical data published in the journal Anesthesia and Analgesia.

Investigators at Temple University assessed the effect of CBD in an animal model of on paclitaxel-induced allodynia (pain resulting from an otherwise innocuous stimulus).

"We found that cannabidiol completely prevented the onset of the neuropathic, or nerve pain caused by the chemo drug Paclitaxel, which is used to treat breast cancer," said the study's lead investigator.

Researchers concluded, "Our preliminary findings therefore indicate that cannabidiol may ... therefore be effective at preventing dose-limiting paclitaxel-induced peripheral neuropathy in humans.

Cannabidiol has been previously shown to inhibit breast cancer metastasis in preclinical settings.

In 2010, a series of FDA-approved clinical trials concluded that inhaled cannabis significantly reduces neuropathy compared to placebo in human subjects. "There is good evidence now that cannabinoids may be either an adjunct or a first-line treatment for ... neuropathy," researchers concluded.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice," appears in the October edition of journal Anesthesia and Analgesia.

Mayo Clinic Finds Massive Fraud In Cancer Research

Original Link

New Discovery Shakes the Foundation of Cancer Research

Posted By Dr. Mercola | October 15 2011 | 33,082 views

Story at-a-glance

Two widely cited, published cancer research studies contain fabricated data, will be retracted The Mayo Clinic concluded that data about harnessing the immune system to fight cancer had been fabricated, resulting in the retraction of 17 papers in nine research journals Cancer research in the United States needs to be scrutinized, as much is money-driven and based on developing new drugs

By Dr. Mercola

In a scandal that has reverberated around the world of cancer research, the Office of Research Integrity at the U.S. Department of Health found that a Boston University cancer scientist fabricated his findings. His work was published in two journals in 2009, and he’s been ordered to retract them. But important studies by other scientists like those at the Mayo Clinic, who based their work on his findings, could now make 10 years of their studies worthless, according to commentary in Gaia Health.

It seems fairly evident that the cancer industrial complex is a highly lucrative, well-oiled system that tends to support funding for expensive drug treatments that don't address the cause of the problem, and have yet to make a significant dent in the decrease of the overall cancer rate in the US despite investing hundreds of billions of dollars. Much of the support comes from flawed and biased "research" studies that support the use of expensive drugs as detailed in the featured articles.

Researchers, too, are well aware of the notoriety and money to be found in cancer research … particularly what may be deemed successful cancer research (which unfortunately is often measured by the discovery of new drug treatments). But, as with many areas of medical research, it's important to read between the lines of "scientifically proven" studies, even those that are well accepted.

Often what you'll find is the research gives the perception of science when really it is a heavily manipulated process designed to control and deceive. Case in point, here again we have an example of widely accepted, published research that turned out to be fabricated.

10 Years of Cancer Research Down the Drain

The Office of Research Integrity (ORI) at the U.S. Department of Health reported in August 2011 that final action has been taken against Sheng Wang, PhD, of Boston University School of Medicine, Cancer Research Center. ORI states:

"The Respondent engaged in research misconduct by fabricating data that were included in two (2) published papers."

This includes:

• Oncogene February 2009, which found that HIC1, a protein thought to suppress tumor growth, is a "central molecule in a novel mechanism controlling cell growth and that the disruption of this HIC1-mediated pathway may lead to abnormal cell proliferation and, ultimately, cancer."
• Molecular Endocrinology December 2009, which found "reintroducing HIC1 into resistant breast cancer cells restored their sensitivity to the estrogen antagonists, indicating the existence of a novel regulatory mechanism for growth control of breast cancer cells."

Specifically, six of the eight figures in the Oncogene paper and six of the seven figures in the Molecular Endocrinology study were said to contain data from fabricated experiments. Though Wang is now required to retract the papers, and he reportedly stopped working for Boston University in July, he will only be ineligible for federal funding for 2 years.

Further, the fabricated research may continue to live on, as it has been cited by other studies and once a finding is accepted in the medical community, it's very hard to make it go away. Unfortunately, scientific retractions are actually becoming increasingly common.

As the Wall Street Journal reported:

"Just 22 retraction notices appeared in 2001, but 139 in 2006 and 339 last year. Through seven months of this year, there have been 210, according to Thomson Reuters Web of Science, an index of 11,600 peer-reviewed journals world-wide …

At the Mayo Clinic, a decade of cancer research, partly taxpayer-funded, went down the drain when the prestigious Minnesota institution concluded that intriguing data about harnessing the immune system to fight cancer had been fabricated. Seventeen scholarly papers published in nine research journals had to be retracted. A researcher, who protests his innocence, was fired. In another major flameout, 18 research journals have said they are planning to retract a total of 89 published studies by a German anesthesiologist …"

read more at here...

Two Words You Should Never Utter to Your Doctor

Link

Posted By Dr. Mercola | September 24 2011 | 52,718 views

Next

Total Video Length: 1:13:07
Download Interview Transcript

Visit the Mercola Video Library

Cut Poison Burn from Nehst on Vimeo.

Important! The producers of this powerful film are allowing a full and FREE preview through TODAY! Please tell everyone you know to watch this film in its entirety TODAY. Please support the film by purchasing a copy for only $10 below!

Story at-a-glance

In the US, parents, shockingly, can lose their children if they refuse conventional cancer therapy. Child Protective Services are routinely called in to charge parents who want a "second opinion" - perhaps to investigate alternative therapies, charging them with child abuse and neglect when refusing conventional treatment. The documentary film Cut Poison Burn follows the tragic case of Jim and Donna Navarro, who fought the medical monopoly in an effort to save their son, Thomas, who was diagnosed with brain cancer at the age of four. Four primary organizations making life and death decisions about you and your family include the FDA, the American Cancer Society, the National Cancer Institute, and the child services system. These are the white-collar bureaucrats whose primary objective is to protect Big Pharma profits and the cancer industry itself. To address this kind of medical injustice, educate yourself and become familiar with your local representatives so you can educate them. Also help support Navarro's legislation to protect Patient's Rights, soon to be reintroduced.

By Dr. Mercola

You may recognize Jim Navarro from the documentary film Cut Poison Burn, which I recently posted. You can watch the entire film for free. If you haven't seen it yet, I urge you to take the time to view it now.

Jim is the father of Thomas Navarro, who at the age of four was diagnosed with medulloblastoma, a type of brain cancer. The family ended up in a protracted battle against the medical monopoly after objecting to the conventional treatment, choosing instead to seek out less invasive, less damaging, and less life threatening approaches. However, the medical system's response was swift and callous.

In fact, in the months that followed Thomas' diagnosis, the family went into hiding to keep their son away from the authorities who threatened to take him into custody, charging Jim and Donna Navarro with child abuse and neglect.

The Navarro's wanted to use Dr. Burzynski's non-toxic, highly successful antineoplaston treatment instead of conventional chemotherapy and radiation. However, the FDA went to great lengths to prevent Thomas from receiving the therapy, and only after extensive legal wrangling, great expense, and being forced to submit to conventional treatment first did the family finally receive approval to use Dr. Burzynski. Unfortunately, at that point it was too late. The damage from the chemo was too great, and he lost his battle with cancer at the tender age of six. His death certificate states the cause of death as:

Respiratory failure due to chronic toxicity of chemotherapy

Since the death of his son, Jim Navarro has been championing a patient's rights act to prevent this tragic injustice from occurring again.

For full article please follow link at the top

Guest Post: Power over Cancer

submitted by David Haas

Power over Cancer

Not too long ago, cancer patients did not have the luxury of joining a cancer support group.; Now, cancer patients can join online groups and still receive the same benefits as in-person groups. However, some people do not understand just how important these support groups are to cancer patients. There are groups that help people have or have gone through all different types of cancer including but not limited to breast cancer, colon cancer, and even rare cancers such as mesothelioma.

Often times, when patients undergo extensive cancer treatment, their positive sense of well-being diminishes. Moreover, their body has to work extra hard to repair the healthy tissues and cells that the surgery and radiation treatment kills. These combined, can really hurt a person's sense of well-being, optimism, and positive outlook.

However, studies show that there is power in numbers, and this also applies to cancer support groups. Here are a few ways that cancer support groups help cancer patients.

It allows them to talk about their feelings

It is not healthy to bottle up your feelings and worries. Cancer support groups, like the American Cancer Society, are designed to help patients express what is on their mind, helping them to explain their worries. After talking about their fears, patients can feel relief knowing they have told someone else what they are feeling who is going through the same thing.

It helps them understand their condition

Patients in remission can teach new patients what they should expect and what it will be like. Knowing this can help patients be prepared mentally and emotionally for their future, something doctors can rarely do for patients. Additionally, some patients don't understand everything their doctor tells them, usually because of stress and worry. In a relaxed setting, other patients can answer the new patient's questions, helping them even more to feel comfortable about their condition.

It is therapeutic

Patients who are in remission often have a sense of obligation to help new patients. Therefore, cancer support groups are just as much for patients who are in remission and also cancer-free. It allows them the opportunity to have closure about their condition and help new patients at the same time. This article from cancer.about.com, also details how cancer support groups are therapeutic.

Conclusion

Virtually anyone can attend a cancer support group, even friends and family of people with cancer, or people who just want to learn more about cancer. Additionally, patients can also join online support groups, making it very easy to find a community of people who are going through the exact same cancer treatment.

By: David Haas

New Cancer Drug Price May Top $100,000

Seattle Genetics cancer drug price may top $100,000
By Alina Selyukh | Reuters

WASHINGTON (Reuters) - The price of Seattle Genetics Inc's blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.

The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin's lymphoma since 1977.

Seattle Genetics on Monday said the drug will cost $4,500 per vial. In its clinical trials, the company said, patients on average received three vials per dose and between seven and nine doses per treatment.

The total price would then generally vary from $94,500 to $121,500 per patient, within Wall Street's expected range.

The drugmaker's shares were down 2.3 percent to $14.70 in afternoon trading on Nasdaq, underperforming the Nasdaq Biotech index, which was down 0.3 percent.

"Seattle Genetics' decision to price Adcetris north of $100,000 seems to be causing some concern in the investment community following the recent failure of Dendreon's Provenge to live to up to sales expectations," said Morningstar Inc analyst Lauren Migliore.

Adcetris is the latest cancer drug to hit the market with a hefty pricetag to the discontent of patient groups.

Earlier this month, Dendreon Corp lost two-thirds of its market value when it could not deliver on promised sales of its prostate cancer vaccine Provenge, which costs about $93,000 per course, as doctors weren't confident enough about getting reimbursed.

"I think you get a reason for pushback (against highly-priced cancer drugs) because many of these cancer drugs are really not that effective, but in this case I think it's one of the most effective drugs out there," Leerink Swann analyst Howard Liang said of Adcetris.

"I would think that the pricing is high but it's not outrageous compared to other cancer drugs."

In March, U.S. regulators approved Bristol Myers Squibb Co's Yervoy for patients with advanced melanoma, a deadly skin cancer. A course of treatment with Yervoy costs about $120,000.

Earlier in August the FDA approved another melanoma drug, Zelboraf by Roche Holding, which costs about $56,400 for a six-month course of treatment.

"Life science companies are aware of the debt and deficit situation in Washington, D.C., and that indirectly limiting Medicare and Medicaid drug prices could be on the horizon," said Ipsita Smolinski, senior health policy analyst at Capitol Street.

For Adcetris, however, the patient population is generally younger and so more likely to rely on private insurance than federal programs, making the pricetag less controversial, analysts said.

About 9,000 Americans a year are diagnosed with Hodgkin's lymphoma and 3,000 with ALCL.

(Reporting by Alina Selyukh; Editing by Tim Dobbyn)

@yahoonews on Twitter, become a fan on Facebook

http://news.yahoo.com/seattle-genetics-cancer-drug-price-may-top-100-182806648.html